Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer

Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Immune checkpoint inhibitors (ICIs), including programmed cell death 1 (PD-1) antibody, programmed cell death ligand 1 (PD-L1) antibody, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chinese Society of Clinical Oncology, Expert Committee on Tumor Vascular-targeted Therapy, Chinese Society of Clinical Oncology, Expert Committee on Non-small Cell Lung Cancer
Formato: article
Lenguaje:ZH
Publicado: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2021
Materias:
lung neoplasms
immunotherapy
immune checkpoint inhibitors
tumor mutational burden
expert consensus
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/73efbbca7aad481c9495e49e699bda8c

Ejemplares similares